MaxCyte Inc.

11/30/2023 | Press release | Distributed by Public on 11/30/2023 01:05

Exercise of options and PDMR dealing

MaxCyte, Inc.

("MaxCyte" or the "Company")

Exercise of options and PDMR dealing

ROCKVILLE, MD, November 30, 2023:MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 27 November 2023, as per a filing lodged with the U.S. Securities and Exchange Commission, John Johnston, aNon-Executive Director of the Company, exercised options over 5,000 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 5,000 new shares of Common Stock were issued pursuant to the Company's existing its block admission facility and were sold by John Johnston at a price range between $4.52 and $4.63 per Common Stock ("Sale"). The sold shares represent approximately 1.6% of John Johnston's total equity and option holdings in the Company's stock capital, respectively.

Following the Exercise and Sale, John Johnston holds 120,583 shares of Common Stock representing 0.1% of the issued stock capital of the Company. Following the Exercise, John Johnston holds a further 182,217 options over Common Stock.

The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by John Johnston on 28 March 2023 relating solely to the sale of shares acquired from exercise of options that expire on 4 March 2029.

MaxCyte Contacts:

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

[email protected]

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

UK IR Adviser

ICR Consilium

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

[email protected]

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation®technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™,GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. Byproviding our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more atmaxcyte.comand follow us onTwitterandLinkedIn.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

John Johnston

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Common Stock of $0.01 each



Identification code

US57777K1060



b)

Nature of the transaction

Exercise of Options overcommon stock

c)

Price(s) and volume(s)







Exercise Price(s)

Volume(s)




$2.142

5,000







d)

Aggregated information




- Aggregated volume

5,000



- Price

$2.142



e)

Date of the transaction

27 November 2023

f)

Place of the transaction

US Stock Exchange, Nasdaq

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

John Johnston

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MaxCyte Inc.

b)

LEI

54930053YHXULRFCU991

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Common Stock of $0.01 each



Identification code

US57777K1060



b)

Nature of the transaction

Sale ofcommon stock

c)

Price(s) and volume(s)







Exercise Price(s)

Volume(s)




$4.5200

28




$4.5300

200




$4.5400

130




$4.5500

597




$4.5550

26




$4.5600

388




$4.5650

226




$4.5700

127




$4.5750

100




$4.5900

134




$4.5950

100




$4.6000

74




$4.6050

735




$4.6150

1085




$4.6200

452




$4.6250

226




$4.6300

372







d)

Aggregated information




- Aggregated volume

5,000



- Price

$4.5918



e)

Date of the transaction

27 November 2023

f)

Place of the transaction

US Stock Exchange, Nasdaq